FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2117443261> ?p ?o ?g. }

• W2117443261 endingPage "418" @default.
• W2117443261 startingPage "404" @default.
• W2117443261 abstract "Retinoids are potent cell growth and differentiation modulators, but cellular effects of therapeutic retinoids in psoriasis are unknown. We studied the effects of etretinate on pathological activation of keratinocytes and lymphocytes in patients treated systemically with this agent for 8 weeks. Ten patients with extensive psoriasis vulgaris were treated with etretinate at 0.75 mg/kg for 8 weeks. Skin biopsies obtained before and at 8 weeks of treatment were studied using immunohistochemical markers for keratinocyte proliferation or differentiation and for the presence of T-lymphocyte subsets or associated inflammatory proteins. During 8 weeks of treatment, the clinical severity decreased by a mean of 64% (p < 0.001). Compared to a similar group of patients treated with bath PUVA, psoriatic plaque erythema resolved more slowly and less completely (p < 0.05), but improvements in plaque thickness and scale were not significantly different between etretinate and PUVA treatments. Etretinate produced a 44% decrease in epidermal thickness (p < 0.001) and a 62% reduction in keratinocyte proliferation (p < 0.001) after 8 weeks of treatment. Unexpectedly, keratinocyte differentiation was enhanced following etretinate treatment as indicated by increased filaggrin production, increased number and size of keratohyaline granules, greater abundance of keratin filaments, and increased secretion of intercellular lipids from Odland bodies. The stratum corneum in resolving psoriatic lesions was unusually thin, probably caused by retinoid-induced shedding of corneocytes. “Regenerative” epidermal growth was maintained during etretinate treatment, as marked by continued expression of keratin 16 and a3-integrin by suprabasal keratinocytes. Surprisingly, the inflammation-associated proteins HLA-DR and ICAM-1 were no longer produced by epidermal keratinocytes following etretinate treatment, and CD3+, CD8+, and CD25+ T-lymphocyte subsets were reduced by 50-65% in lesional tissue (p < 0.01). Etretinate shows unexpected anti-inflammatory and pro-differentiation actions in psoriasis. Etretinate appears to function as a disease suppressive agent which improves hyperplasia, keratinocyte differentiation and tissue inflammation mediated by cellular immune elements." @default.
• W2117443261 created "2016-06-24" @default.
• W2117443261 creator A5048580223 @default.
• W2117443261 creator A5049264583 @default.
• W2117443261 creator A5049859852 @default.
• W2117443261 creator A5050777837 @default.
• W2117443261 creator A5061063698 @default.
• W2117443261 creator A5080337749 @default.
• W2117443261 date "1996-10-01" @default.
• W2117443261 modified "2023-10-16" @default.
• W2117443261 title "Cellular actions of etretinate in psoriasis: enhanced epidermal differentiation and reduced cell-mediated inflammation are unexpected outcomes" @default.
• W2117443261 cites W1524819295 @default.
• W2117443261 cites W1968444092 @default.
• W2117443261 cites W1981474045 @default.
• W2117443261 cites W1984099131 @default.
• W2117443261 cites W1996513552 @default.
• W2117443261 cites W2005139238 @default.
• W2117443261 cites W2019222650 @default.
• W2117443261 cites W2024141481 @default.
• W2117443261 cites W2026199417 @default.
• W2117443261 cites W2027812158 @default.
• W2117443261 cites W2029249496 @default.
• W2117443261 cites W2038226782 @default.
• W2117443261 cites W2044006125 @default.
• W2117443261 cites W2048896146 @default.
• W2117443261 cites W2058458929 @default.
• W2117443261 cites W2067957471 @default.
• W2117443261 cites W2081454227 @default.
• W2117443261 cites W2098857341 @default.
• W2117443261 cites W2105786952 @default.
• W2117443261 cites W2113026828 @default.
• W2117443261 cites W2117646004 @default.
• W2117443261 cites W2142875711 @default.
• W2117443261 cites W2162145196 @default.
• W2117443261 cites W2335505871 @default.
• W2117443261 cites W2488121905 @default.
• W2117443261 cites W4233524499 @default.
• W2117443261 cites W4246582917 @default.
• W2117443261 doi "https://doi.org/10.1111/j.1600-0560.1996.tb01430.x" @default.
• W2117443261 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/8915849" @default.
• W2117443261 hasPublicationYear "1996" @default.
• W2117443261 type Work @default.
• W2117443261 sameAs 2117443261 @default.
• W2117443261 citedByCount "44" @default.
• W2117443261 countsByYear W21174432612013 @default.
• W2117443261 countsByYear W21174432612014 @default.
• W2117443261 countsByYear W21174432612015 @default.
• W2117443261 countsByYear W21174432612016 @default.
• W2117443261 countsByYear W21174432612020 @default.
• W2117443261 countsByYear W21174432612021 @default.
• W2117443261 countsByYear W21174432612022 @default.
• W2117443261 countsByYear W21174432612023 @default.
• W2117443261 crossrefType "journal-article" @default.
• W2117443261 hasAuthorship W2117443261A5048580223 @default.
• W2117443261 hasAuthorship W2117443261A5049264583 @default.
• W2117443261 hasAuthorship W2117443261A5049859852 @default.
• W2117443261 hasAuthorship W2117443261A5050777837 @default.
• W2117443261 hasAuthorship W2117443261A5061063698 @default.
• W2117443261 hasAuthorship W2117443261A5080337749 @default.
• W2117443261 hasConcept C105702510 @default.
• W2117443261 hasConcept C142724271 @default.
• W2117443261 hasConcept C16005928 @default.
• W2117443261 hasConcept C179927520 @default.
• W2117443261 hasConcept C190684412 @default.
• W2117443261 hasConcept C203014093 @default.
• W2117443261 hasConcept C2776088058 @default.
• W2117443261 hasConcept C2776458125 @default.
• W2117443261 hasConcept C2776705134 @default.
• W2117443261 hasConcept C2776914184 @default.
• W2117443261 hasConcept C2777074287 @default.
• W2117443261 hasConcept C2778329239 @default.
• W2117443261 hasConcept C2778370115 @default.
• W2117443261 hasConcept C2780564577 @default.
• W2117443261 hasConcept C54355233 @default.
• W2117443261 hasConcept C71924100 @default.
• W2117443261 hasConcept C81241287 @default.
• W2117443261 hasConcept C81885089 @default.
• W2117443261 hasConcept C86803240 @default.
• W2117443261 hasConceptScore W2117443261C105702510 @default.
• W2117443261 hasConceptScore W2117443261C142724271 @default.
• W2117443261 hasConceptScore W2117443261C16005928 @default.
• W2117443261 hasConceptScore W2117443261C179927520 @default.
• W2117443261 hasConceptScore W2117443261C190684412 @default.
• W2117443261 hasConceptScore W2117443261C203014093 @default.
• W2117443261 hasConceptScore W2117443261C2776088058 @default.
• W2117443261 hasConceptScore W2117443261C2776458125 @default.
• W2117443261 hasConceptScore W2117443261C2776705134 @default.
• W2117443261 hasConceptScore W2117443261C2776914184 @default.
• W2117443261 hasConceptScore W2117443261C2777074287 @default.
• W2117443261 hasConceptScore W2117443261C2778329239 @default.
• W2117443261 hasConceptScore W2117443261C2778370115 @default.
• W2117443261 hasConceptScore W2117443261C2780564577 @default.
• W2117443261 hasConceptScore W2117443261C54355233 @default.
• W2117443261 hasConceptScore W2117443261C71924100 @default.
• W2117443261 hasConceptScore W2117443261C81241287 @default.
• W2117443261 hasConceptScore W2117443261C81885089 @default.
• W2117443261 hasConceptScore W2117443261C86803240 @default.
• W2117443261 hasIssue "5" @default.

• next